Hikal Limited (NSE:HIKAL)
418.85
+17.65 (4.40%)
Apr 2, 2025, 3:30 PM IST
Hikal Revenue
Hikal had revenue of 4.48B INR in the quarter ending December 31, 2024, with 0.03% growth. This brings the company's revenue in the last twelve months to 18.22B, up 0.31% year-over-year. In the fiscal year ending March 31, 2024, Hikal had annual revenue of 17.85B, down -11.79%.
Revenue (ttm)
18.22B
Revenue Growth
+0.31%
P/S Ratio
n/a
Revenue / Employee
8.84M
Employees
2,061
Market Cap
51.63B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 17.85B | -2.38B | -11.79% |
Mar 31, 2023 | 20.23B | 803.09M | 4.13% |
Mar 31, 2022 | 19.43B | 2.22B | 12.92% |
Mar 31, 2021 | 17.20B | 2.13B | 14.14% |
Mar 31, 2020 | 15.07B | -823.46M | -5.18% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 516.03B |
Divi's Laboratories | 90.78B |
Cipla | 267.20B |
Mankind Pharma | 116.41B |
Apollo Hospitals Enterprise | 211.46B |
Zydus Lifesciences | 222.47B |
Aurobindo Pharma | 309.22B |
Alkem Laboratories | 127.57B |
Hikal News
- 7 weeks ago - Hikal shares drop over 6% after US FDA issues six observations for Jigani facility - Business Upturn
- 7 weeks ago - Hikal receives 6 observations for Jigani facility from US FDA - Business Upturn